NanoViricides Inc. (NNVC)

[found_it]

NV-INF-1, INJECTABLE FLUCIDE™ FOR TREATMENT OF HOSPITALIZED PATIENTS WITH INFLUENZA



NanoViricides, Inc. (NYSE-MKT stock symbol: NNVC) is a pioneering company developing nanomedicines against viruses. A "nanoviricide(r)" as defined by the company, is a drug that is designed to bind to the virus particle, encapsulate it, and possibly dismantle it. The nanoviricide drugs are developed using a unique polymeric micelle technology. Each polymer chain comprises a homopolymer of a proprietary monomer that contains PEG in the backbone. At each monomer unit, the polymer chain has pendant alkyl chains that lead to self-assembled surfactant-like polymeric micelles. At each monomer unit, the Company attaches multiple proprietary anti-viral ligands that direct the polymeric micelle to specifically bind to a virus or virus family. The Company designs the virus-binding ligands to mimic the virus-binding sites of the cognate receptor(s) of the virus. Thus, no matter how much the virus mutates, it is expected to continue to be affected by the nanoviricide, since the cognate receptor binding does not change. INF-001, Injectable FluCide™ , is the Company's first lead candidate for the treatment of hospitalized patients with influenza. INF-001 has shown as much 3 log reduction in lung viral load, and has shown full 21 day survival in lethal mouse model studies, wherein oseltamivir treatment led to only 8 days survival. It was shown to be effective against both Type I (H1N1) and Type II (H3N2) influenza viruses in vivo. The Company has recently completed construction of a cGMP-capable manufacturing facility for the scale-up and production of nanaomedicines in kg-scale, to enable supply for human clinical studies. The Company is also developing a drug candidate against Ebola in response to the current epidemic.

iirusa.com

Above from the Theraputic Area Partnerships conference details: November 18-20, 2015
Hilton Back Bay, Boston, MA